BioHarvest Sciences Inc. (BHST)
| Market Cap | 41.71M -71.4% |
| Revenue (ttm) | 35.48M +17.5% |
| Net Income | -11.07M |
| EPS | -0.53 |
| Shares Out | 22.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,822 |
| Open | 1.840 |
| Previous Close | 1.850 |
| Day's Range | 1.830 - 1.913 |
| 52-Week Range | 1.820 - 12.800 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+470.65%) |
| Earnings Date | Aug 11, 2026 |
About BHST
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, ... [Read more]
Financial Performance
In 2025, BioHarvest Sciences's revenue was $34.51 million, an increase of 37.00% compared to the previous year's $25.19 million. Losses were -$11.14 million, -13.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BHST stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 470.65% from the latest price.
News
BioHarvest Sciences Transcript: Q3 Investor Summit Group Virtual Conference 2026
A highly experienced team has developed a patented platform for industrial-scale plant cell culture, enabling scalable, sustainable production of proprietary molecules for multiple industries. Commercial success with VINIA and new supply agreements support strong revenue growth projections through 2028.
BioHarvest Sciences management to meet virtually with Craig-Hallum
Virtual Meeting to be held on August 18-21 hosted by Craig-Hallum.
BioHarvest Sciences price target lowered to $8 from $10 at Roth Capital
Roth Capital lowered the firm’s price target on BioHarvest Sciences (BHST) to $8 from $10 and keeps a Buy rating on the shares. The firm cites the company’s Q2 results…
BioHarvest Sciences price target lowered to $5 from $12 at Maxim
Maxim analyst Anthony Vendetti lowered the firm’s price target on BioHarvest Sciences (BHST) to $5 from $12 and keeps a Buy rating on the shares. The company reported Q2 revenue…
BioHarvest Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
A platform-based plant cell culture company highlighted its patented, non-GMO technology, robust product pipeline, and recent $20–30 million fragrance deal. Revenue guidance for this year is $37–40 million, with profitability expected next year and expansion plans underway.
BioHarvest Sciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 3.8% year-over-year to $8.8M, with a net loss of $3.7M and gross margin at 58%. The company secured its first major CDMO fragrance contract, expects $20M-$30M revenue from it by 2028, and revised 2026 revenue guidance to $37M-$40M, targeting EBITDA breakeven in 2027.
BioHarvest Sciences Earnings release: Q2 2026
BioHarvest Sciences released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
BioHarvest Sciences Slides: Corporate presentation
BioHarvest Sciences has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth ...
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional co...
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant...
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis...
BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest's CDMO customers ...
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant...
BioHarvest Sciences to Present at the 2026 BIO International Convention
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant...
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Re...
BioHarvest Sciences Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 8% year-over-year to $8.5M, with gross margin up to 59% and net loss at $2.6M. D2C and CDMO segments advanced, including a $1.2M fragrance contract and strong VINIA product adoption. Guidance for 2026 remains unchanged, with growth expected in H2.
BioHarvest Sciences Earnings release: Q1 2026
BioHarvest Sciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% Y...
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, ...
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-pro...
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Re...
BioHarvest Sciences Slides: Corporate presentation
BioHarvest Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its propr...
BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy
Ilan Sobel joins Board of Directors with focused mandate on D2C growth. Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and ...